<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770610</url>
  </required_header>
  <id_info>
    <org_study_id>OT_101_001</org_study_id>
    <nct_id>NCT04770610</nct_id>
  </id_info>
  <brief_title>Study of OT-101 in Treating Myopia</brief_title>
  <official_title>A Phase III, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocumension (Hong Kong) Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Statistics &amp; Data Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ocumension (Hong Kong) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, randomized, double-masked, placebo-controlled, parallel-group,&#xD;
      multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an&#xD;
      investigational treatment for myopia in pediatric subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, randomized, double-masked, placebo-controlled, parallel-group,&#xD;
      multi-center study to evaluate the safety tolerability and efficacy of OT-101 (Atropine&#xD;
      0.01%) Ophthalmic Solution in treating the progression of myopia in pediatric subjects that&#xD;
      will enroll approximately 678 pediatric subjects with myopia in total. Subjects will be&#xD;
      stratified by age and refractive error.&#xD;
&#xD;
      This study consists of 11 visits over the course of approximately 4 years and can be broken&#xD;
      down in the 3 stages: Screening (Days -14 to -1), Stage 1 (Day 1 to Year 3), and Stage 2&#xD;
      (Year 3 to Year 4). In stage 1, subjects will be randomized in a 2:1 manner to OT-101&#xD;
      Ophthalmic Solution: Placebo. Subjects will be dosed with one drop of study treatment per eye&#xD;
      once daily at bedtime for 3 years. In stage 2, subjects will be re-randomization 1:1 will&#xD;
      occur at Visit 9 (Month 36). At re-randomization, subjects who had been assigned to OT-101&#xD;
      Ophthalmic Solution will be randomized in a 1:1 ratio to continue on OT-101 Ophthalmic&#xD;
      Solution or switch to placebo. Subjects who had been assigned to placebo will continue with&#xD;
      placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of study eyes with a -0.75D of progressive myopia defined as an increase in spherical equivalent of -0.75D or greater as assessed by cycloplegic autorefraction.</measure>
    <time_frame>At month 36</time_frame>
    <description>Efficacy of OT-101 Ophthalmic Solution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in spherical equivalent (D) in the study eye as assessed by cycloplegic autorefraction</measure>
    <time_frame>Baseline to Month 36</time_frame>
    <description>Efficacy of OT-101 Ophthalmic Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in study eye axial length as measured by cycloplegic biometry (a standardized device will be selected for this study)</measure>
    <time_frame>Baseline to Month 36</time_frame>
    <description>Efficacy of OT-101 Ophthalmic Solution</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">678</enrollment>
  <condition>Myopia, Progressive</condition>
  <arm_group>
    <arm_group_label>OT-101 alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atropine Sulfate 0.01% Ophthalmic Solution through year 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OT-101 plus vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atropine Sulfate 0.01% Ophthalmic Solution through year 3 followed by vehicle for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle (Investigational Product minus active ingredient) through year 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OT-101 Ophthalmic Solution</intervention_name>
    <description>Atropine 0.01%</description>
    <arm_group_label>OT-101 alone</arm_group_label>
    <arm_group_label>OT-101 plus vehicle</arm_group_label>
    <other_name>Investigational Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Investigational Product minus active ingredient</description>
    <arm_group_label>OT-101 plus vehicle</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have refractive error by cycloplegic autorefraction at baseline (Visit 1) in the study&#xD;
             eye of:&#xD;
&#xD;
               1. myopia greater or equal to -1.00D of spherical equivalent&#xD;
&#xD;
               2. astigmatism less than or equal to 1.50DC&#xD;
&#xD;
               3. progression of at least -0.50D of spherical equivalent in the last 12 months;&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Have active or a history of chronic or recurrent episodes of ocular inflammation (e.g.&#xD;
             moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative&#xD;
             keratitis, scleritis) in either eye;&#xD;
&#xD;
          -  Have undergone any myopia control treatment including orthokeratology, rigid&#xD;
             gas-permeable contact lenses, bifocal contact lenses, progressive addition spectacle&#xD;
             lenses, or other lenses to reduce myopia progression in the previous 6 months. Myopic&#xD;
             correction in the form of single-vision eyeglasses and/or single-vision soft contact&#xD;
             lenses are allowed;&#xD;
&#xD;
          -  Have undergone any form of refractive eye surgery including incisional keratotomy,&#xD;
             photorefractive keratectomy [PRK], laser in situ keratomileusis [LASIK],&#xD;
             laser-assisted sub- epithelial keratectomy [LASEK]), corneal inlay procedures,&#xD;
             conductive keratoplasty, small incision lenticule extraction (SMILE), cataract&#xD;
             extraction, or any form of intraocular lens implantation;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Lane</last_name>
    <role>Study Director</role>
    <affiliation>ORA, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamara Whitman</last_name>
    <phone>205-910-8028</phone>
    <email>twhitman@oraclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>North Valley Eye Medical Group, Inc.</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Rodriguez</last_name>
      <phone>818-365-0606</phone>
      <email>rrodriguez@northvalleyeye.net</email>
    </contact>
    <investigator>
      <last_name>Robert Smyth-Medina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Vision Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Agbo</last_name>
      <phone>719-559-2020</phone>
      <email>helene@vicolorado.com</email>
    </contact>
    <investigator>
      <last_name>Erik Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Physicians Pediatric Ophthalmology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katherine Haider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care, Ltd.</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Frohmann</last_name>
      <phone>636-390-3999</phone>
      <phone_ext>294</phone_ext>
      <email>karaf@geccobilling.com</email>
    </contact>
    <investigator>
      <last_name>Michael Korenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Associates</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Hindman, OD</last_name>
      <phone>724-772-3000</phone>
      <email>nhindman@scottandchristie.com</email>
    </contact>
    <investigator>
      <last_name>William Christie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Antonio Eye Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Mainez</last_name>
      <phone>210-226-6169</phone>
      <phone_ext>3004</phone_ext>
      <email>jmainez@saeye.com</email>
    </contact>
    <investigator>
      <last_name>Manpreet Chhabra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpine Research Organization</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Kenley</last_name>
      <email>lexi@alpine-research.com</email>
    </contact>
    <investigator>
      <last_name>Jared Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Myopia, Degenerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

